Pancreatic cancer diagnosis marker based on external vesicle miRNA and application thereof
The use of specific miRNA pairs in pancreatic cancer diagnostic markers addresses the issues of low sensitivity and repeatability in current methods, providing accurate and stable early detection through expression level ratios, enhancing diagnostic performance.
Patent Information
- Application Number
- CN202411480045.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-22
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2044-10-22
AI Technical Summary
Current diagnostic methods for pancreatic cancer suffer from low sensitivity, low specificity, and poor repeatability due to unstable expression of internal reference genes, leading to inaccurate and unreliable diagnostic results, especially in early detection.
A diagnostic or prognostic marker combination for pancreatic cancer comprising specific miRNA pairs, such as hsa-miR-98/hsa-miR-25, hsa-miR-378i/hsa-miR-150, hsa-miR-501/hsa-miR-150, hsa-miR-378i/hsa-miR-155, hsa-miR-193a/hsa-miR-155, and hsa-miR-150/hsa-miR-1180, which are used to calculate expression level ratios without relying on conventional internal reference genes, and combined with CA19-9 for improved accuracy.
The miRNA pairs provide highly sensitive and specific diagnostic markers that offer stable and repeatable results across different data centers, effectively distinguishing pancreatic cancer from benign diseases and healthy samples, with high sensitivity for early detection.
Smart Images

Figure BDA0005097217140000071 
Figure BDA0005097217140000091 
Figure BDA0005097217140000101
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical detection technology, and specifically relates to a pancreatic cancer diagnostic marker based on extracellular vesicle miRNA and its application. Background Art
[0002] Pancreatic cancer (PC) is one of the most lethal malignancies in the world, with almost equal morbidity and mortality. Due to the rapid progression of the disease and the hidden early symptoms, only 15%-20% of patients are diagnosed in the early stage. Currently, the morbidity and mortality of pancreatic cancer are increasing year by year, whether in the United States, Europe, Japan or China. It is estimated that by 2050, the global incidence of pancreatic cancer will reach 18.6 per 100,000 people, with an average annual increase of 1.1%, which will put great pressure on the public health system. The high mortality rate of pancreatic cancer is mainly attributed to the special anatomical location of the pancreas and non-specific symptoms, resulting in many cases being discovered and diagnosed at a late stage, when obvious clinical symptoms usually appear. Globally, the 5-year survival rate of pancreatic cancer is generally less than 10%, with little difference between high-income and low-middle-income countries, and the survival rate is the lowest among all cancers. Despite advances in diagnosis and treatment in recent years, the high mortality rate of pancreatic cancer is still closely related to late detection and the limitations of existing treatments. Therefore, the development of new screening methods, early diagnostic tools and treatment strategies is crucial to improve the prognosis of pancreatic cancer patients.
[0003] The diagnosis of pancreatic cancer mainly relies on imaging and serum tumor markers. Imaging methods include ultrasound, computed tomography (CT) and magnetic resonance imaging (MRI), which are often used to detect obvious pancreatic masses, but they have limitations in early diagnosis, especially for early cases without obvious masses. In addition, the diagnostic results of imaging are easily affected by the operator's experience and equipment performance. The serum marker CA19-9 is the most commonly used indicator in the diagnosis and monitoring of pancreatic cancer, but CA19-9 may be falsely positive in cases of biliary infection, inflammation or obstruction; and CA19-9 may be falsely negative in individuals with negative Lewis antigen; therefore, the early diagnosis effect of CA19-9 as a single indicator is not ideal. In contrast, molecular diagnostic technology provides a more accurate means for auxiliary diagnosis by detecting pancreatic cancer-related genes, proteins and RNA markers. Combining imaging, biomarker detection and molecular diagnostic technology can help improve the accuracy of early screening for pancreatic cancer and provide strong support for improving patient survival.
[0004] Extracellular vesicles are small vesicles that are secreted by cells and enter the body fluid or extracellular environment, playing an important role in intercellular communication. Due to the protection of the lipid bilayer, extracellular vesicles can stably exist in various biological fluids and cell culture fluids; this characteristic makes the contents of extracellular vesicles a reliable tumor marker, and miRNA is a type of extracellular vesicle content. It is reported that extracellular vesicle miRNAs are expressed at different levels in different diseases and physiological conditions, and also play an important regulatory role in the progression of malignant tumors. Therefore, extracellular vesicle miRNAs may become a new form of biomarker for early diagnosis and prognosis tracking of cancer.
[0005] However, the biomarkers for early screening of pancreatic cancer have problems of low sensitivity, low specificity or poor repeatability of diagnostic efficacy. For example, in the prior art, internal reference genes with relatively stable expression are often selected as references to detect the relative expression of the markers. However, existing literature shows that although the expression of the internal reference genes is relatively stable, there are still some differences in the expression of the internal reference genes under different physiological states, resulting in inaccurate relative expression of the markers. The markers or marker combinations screened out in this way will make the repeatability of the diagnostic efficacy worse (i.e., the results are unstable). When the number of samples, sample distribution, etc. change, the accuracy of the diagnostic efficacy will decrease, and the reliability of the markers will decrease. In addition, different batches or different data centers from multiple sources will also lead to unstable results. For example, the markers or marker combinations screened out in a data set center (the results of the same center or institution detection) are prone to unstable results (poor repeatability) when applied to other hospitals or data centers, and even unstable results will occur in different batches. At present, there is still a lack of effective early pancreatic cancer diagnostic kits on the market, so it is urgent to screen out pancreatic cancer diagnostic markers or marker combinations with good repeatability, high reliability and high diagnostic efficacy. Summary of the invention
[0006] Purpose of the Invention
[0007] In response to the problems existing in the above-mentioned prior art methods, the present invention aims to provide a highly sensitive and specific diagnostic or prognostic marker for pancreatic cancer, an analysis system based thereon, a kit or its application, including: an analysis system or kit for predicting pancreatic cancer or evaluating the prognosis of pancreatic cancer, or its application in the preparation of a kit or analysis system for pancreatic cancer diagnosis, efficacy or prognosis evaluation, or related drug evaluation.
[0008] Solution
[0009] To achieve the above object, the present invention provides the following technical solutions:
[0010] In a first aspect, the present invention provides a diagnostic or prognostic marker combination for pancreatic cancer, wherein the diagnostic or prognostic marker for pancreatic cancer comprises a marker combination consisting of at least two or at least four of the following miRNAs:
[0011] hsa-miR-98, hsa-miR-25, hsa-miR-378i, hsa-miR-150, hsa-miR-501, hsa-miR-155, hsa-miR-193a, hsa-miR-1180.
[0012] Furthermore, the diagnostic or prognostic markers for pancreatic cancer include one or more of the following miRNA combinations:
[0013] hsa-miR-98 and hsa-miR-25, optionally, hsa-miR-25 is used to calibrate the relative expression level of hsa-miR-98 (i.e., the expression level ratio of hsa-miR-98 and hsa-miR-25);
[0014] hsa-miR-378i and hsa-miR-150, optionally, hsa-miR-150 is used to calibrate the relative expression level of hsa-miR-378i (i.e., the expression level ratio of hsa-miR-378i and hsa-miR-150);
[0015] hsa-miR-501 and hsa-miR-150, optionally, hsa-miR-150 is used to calibrate the relative expression level of hsa-miR-501 (i.e., the expression level ratio of hsa-miR-501 and hsa-miR-150);
[0016] hsa-miR-378i and hsa-miR-155, optionally, hsa-miR-155 is used to calibrate the relative expression of hsa-miR-378i;
[0017] hsa-miR-193a and hsa-miR-155, optionally, hsa-miR-155 is used to calibrate the relative expression level of hsa-miR-193a (i.e., the expression level ratio of hsa-miR-193a to hsa-miR-155);
[0018] hsa-miR-150 and hsa-miR-1180, optionally, hsa-miR-1180 is used to calibrate the relative expression level of hsa-miR-150 (ie, the expression level ratio of hsa-miR-150 and hsa-miR-1180).
[0019] Furthermore, the detection of the expression level of the marker does not rely on conventional internal reference genes as relative reference or correction.
[0020] Furthermore, the diagnostic or prognostic marker for pancreatic cancer also includes CA19-9.
[0021] Preferably, the diagnostic or prognostic marker for pancreatic cancer comprises one or two of the following miRNA combinations 1) to 2):
[0022] 1) Combination 1: hsa-miR-98, hsa-miR-25, hsa-miR-378i, hsa-miR-150;
[0023] 2) Combination two: hsa-miR-501, hsa-miR-150, hsa-miR-378i, hsa-miR-155, hsa-miR-193a, hsa-miR-1180.
[0024] Further preferably, the miRNA in the miRNA pair is miRNA in serum or plasma.
[0025] Furthermore, the miRNA in the miRNA pair is a miRNA in serum or plasma glycosylated extracellular vesicles.
[0026] In a second aspect, an analysis system for predicting pancreatic cancer or evaluating the prognosis of pancreatic cancer is provided, comprising a data analysis module, wherein the data analysis module is used to analyze the expression level of a marker combination of a target object to be predicted and calculate the ratio of the expression levels of a miRNA pair or directly use the ratio of the expression levels of a miRNA pair as an input feature, and is also used to calculate a prediction value of whether the target object is pancreatic cancer based on the ratio of the expression levels of the miRNA pair; the input feature is selected from at least one of the following ratios of the expression levels of the miRNA pairs:
[0027] hsa-miR-98 / hsa-miR-25;
[0028] hsa-miR-378i / hsa-miR-150;
[0029] hsa-miR-501 / hsa-miR-150;
[0030] hsa-miR-378i / hsa-miR-155;
[0031] hsa-miR-193a / hsa-miR-155;
[0032] hsa-miR-150 / hsa-miR-1180.
[0033] Furthermore, the input features are selected from one or more of the following combinations:
[0034] 1) Combination 1: hsa-miR-98 / hsa-miR-25, hsa-miR-378i / hsa-miR-150;
[0035] 2) Combination two: hsa-miR-501 / hsa-miR-150; hsa-miR-378i / hsa-miR-155; hsa-miR-193a / hsa-miR-155; hsa-miR-150 / hsa-miR-1180.
[0036] Furthermore, a prediction model for outputting a probability value of pancreatic cancer is stored in the data analysis module, wherein the method for constructing the prediction model includes: using the ratio of the expression levels of the miRNA pairs in pancreatic cancer, benign, and healthy samples as input variables, and whether it is pancreatic cancer as the dependent variable, calculating through multivariate logistic regression, obtaining the prediction model, and testing it through a validation set.
[0037] Furthermore, when the detection method is RT-qPCR, the expression ratio is the CT difference of the miRNA pair (the CT value is the conversion of the expression amount, so the CT difference represents the expression ratio).
[0038] Furthermore, the input features also include the expression level of CA19-9 of the target object to be predicted.
[0039] In a third aspect, there is provided a use of the pancreatic cancer diagnostic or prognostic marker combination described in the first aspect in the preparation of a kit or analysis system for pancreatic cancer diagnosis, efficacy or prognosis evaluation, or related drug evaluation.
[0040] In a fourth aspect, there is provided a method for detecting the relative expression of the diagnostic or prognostic marker combination for pancreatic cancer according to the first aspect in serum or plasma glycosylated extracellular vesicles in the preparation of a kit or analysis system for pancreatic cancer diagnosis, efficacy or prognosis evaluation, or related drug evaluation, wherein the marker combination is selected from one of the following combinations:
[0041] 1) Combination 1: the expression level of hsa-miR-98 relative to hsa-miR-25, and the expression level of hsa-miR-378i relative to hsa-miR-150;
[0042] 2) Combination 2: the expression level of hsa-miR-501 relative to hsa-miR-150; the expression level of hsa-miR-378i relative to hsa-miR-155; the expression level of hsa-miR-193a relative to hsa-miR-155; the expression level of hsa-miR-150 relative to hsa-miR-1180.
[0043] In a fifth aspect, a kit is provided for pancreatic cancer diagnosis, efficacy or prognosis assessment, or related drug evaluation, wherein the kit comprises the pancreatic cancer diagnostic or prognostic marker combination and / or its detection reagent described in the first aspect.
[0044] Furthermore, in pancreatic cancer patients, the expression ratio of the miRNA pair in serum glycosylated extracellular vesicles is significantly different from that in healthy humans.
[0045] Furthermore, the detection reagent includes primers and probes for detecting the corresponding miRNA, wherein the primer and probe sequences of each miRNA are as follows:
[0046] The nucleotide sequence of the upstream primer of hsa-miR-150 is shown in SEQ ID NO: 1;
[0047] The nucleotide sequence of the upstream primer of hsa-miR-25 is shown in SEQ ID NO: 2;
[0048] The nucleotide sequence of the upstream primer of hsa-miR-378i is shown in SEQ ID NO: 3;
[0049] The nucleotide sequence of the upstream primer of hsa-miR-98 is shown in SEQ ID NO:4;
[0050] The nucleotide sequence of the upstream primer of hsa-miR-1180 is shown in SEQ ID NO:6;
[0051] The nucleotide sequence of the upstream primer of hsa-miR-501 is shown in SEQ ID NO:7;
[0052] The nucleotide sequence of the upstream primer of hsa-miR-193a is shown in SEQ ID NO:8;
[0053] The nucleotide sequence of the upstream primer of hsa-miR-155 is shown in SEQ ID NO:9;
[0054] The nucleotide sequence of the probe is shown in SEQ ID NO:5;
[0055] The reverse primer is a common downstream primer, and its nucleotide sequence is shown in SEQ ID NO:10.
[0056] Furthermore, primers and probes for conventional internal reference genes are not contained.
[0057] Beneficial Effects
[0058] The diagnostic or prognostic markers for pancreatic cancer provided by the present invention involve miRNA pairs in serum or plasma extracellular vesicles with biological significance, especially miRNA pairs of specific types of glycosylated extracellular vesicles, and the expression ratio of the miRNA pair is used as the input feature of the pancreatic cancer diagnostic model, which avoids the problem of unstable diagnostic performance of existing diagnostic markers caused by instability of internal reference genes, differences in test batches, etc., so that more accurate, stable and repeatable diagnosis or prognostic evaluation can be achieved; the pancreatic cancer diagnostic model constructed by using the expression ratio of the miRNA pair as the model input feature has high diagnostic sensitivity and specificity, and also has great potential in the screening of early pancreatic cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0059] One or more embodiments are exemplarily described by the pictures in the accompanying drawings, and these exemplary descriptions do not constitute limitations on the embodiments. Here, the special word "exemplary" means "used as an example, embodiment, or illustrative". Here, any embodiment described as "exemplary" is not necessarily interpreted as being superior or better than other embodiments.
[0060] Figure 1 This is a heat map of the expression ratios of the 39 paired miRNAs screened in Example 1 on NGS samples.
[0061] Figure 2 This is the LDA graph of the expression ratios of 39 paired miRNAs detected by RT-qPCR in Example 2.
[0062] Figure 3 It is a box plot of the CT value difference of RT-qPCR of the two paired miRNAs in Example 3, wherein, middle and late stage represents the middle and late stage of pancreatic cancer, early stage represents the early stage of pancreatic cancer, benign represents benign diseases, and healthy represents healthy people.
[0063] Figure 4 1 is the ROC curve of pancreatic cancer in different data sets of the pancreatic cancer diagnostic model constructed based on the two paired miRNAs of the preferred combination 1 in Example 3.
[0064] Figure 5 This is a box plot of the model scores constructed based on the two paired miRNAs of the preferred combination 1 in Example 3; wherein, middle and late stages represent middle and late stages of pancreatic cancer, early stages represent early stages of pancreatic cancer, benign represents benign diseases, and healthy represents healthy people.
[0065] Figure 6 It is a box plot of the CT value difference of RT-qPCR of the four paired miRNAs in Example 4, wherein, middle and late stage represents the middle and late stage of pancreatic cancer, early stage represents the early stage of pancreatic cancer, benign represents benign diseases, and healthy represents healthy people.
[0066] Figure 7 The pancreatic cancer ROC curves of the pancreatic cancer diagnostic model constructed based on the four paired miRNAs of the preferred combination 2 in Example 4 in different data sets.
[0067] Figure 8 It is a box plot of the model scores constructed based on the four paired miRNAs of the preferred combination 2 in Example 4; wherein, middle and late stage represents the middle and late stage of pancreatic cancer, early stage represents the early stage of pancreatic cancer, benign represents benign diseases, and healthy represents healthy people.
[0068] Fig. 9 1 is the ROC curve of pancreatic cancer in different data sets of the pancreatic cancer diagnosis model constructed based on the combination of the two paired miRNAs in the preferred combination 1 and the pancreatic cancer indicator CA19-9 in Example 5.
[0069] Fig.10 The pancreatic cancer ROC curves of the pancreatic cancer diagnostic model constructed based on the four paired miRNAs of the preferred combination 2 and the pancreatic cancer indicator CA19-9 in Example 6 in different data sets.
[0070] Fig.11 It is a box plot of the CT value difference of RT-qPCR of the three paired miRNAs in Comparative Example 1, wherein middle and late stages represent middle and late stages of pancreatic cancer, early stages represent early stages of pancreatic cancer, benign represents benign diseases, and healthy represents healthy people.
[0071] Fig.12 1 is the ROC curve of pancreatic cancer in different data sets of the pancreatic cancer diagnosis model constructed based on the three paired miRNAs in combination three in comparative example 1.
[0072] Fig.13 It is a box plot of the expression levels of hsa-miR-98 and hsa-miR-25 corrected by the internal reference gene U6 in Comparative Example 2 (difference in CT values of RT-qPCR), among which, middle and late stages represent middle and late stages of pancreatic cancer, early stages represent early stages of pancreatic cancer, benign represents benign diseases, and healthy represents healthy people. DETAILED DESCRIPTION
[0073] In order to make the purpose, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention. Unless otherwise expressly stated, throughout the specification and claims, the term "including" or its variations such as "comprising" or "including" will be understood to include the stated elements or components, without excluding other elements or other components.
[0074] In addition, in order to better illustrate the present invention, numerous specific details are provided in the specific embodiments below. It should be understood by those skilled in the art that the present invention can also be implemented without certain specific details. In some embodiments, raw materials, elements, methods, means, etc. well known to those skilled in the art are not described in detail, so as to highlight the main purpose of the present invention.
[0075] The reagents, kits, raw materials and equipment used in the following examples, unless otherwise specified, can all be purchased through commercial channels. The experiments or detection methods involved in the present invention, unless otherwise specified, are all conventional experiments or detection methods in the art, or are performed with reference to the corresponding kits or product instructions.
[0076] Example 1: Screening of characteristic miRNA pairs for pancreatic cancer based on serum extracellular vesicle data
[0077] 1. Collection and preparation of clinical data and samples
[0078] Serum samples were collected from pancreatic cancer patients, patients with benign diseases, and healthy subjects. Detailed information is shown in Table 1 .
[0079] All pancreatic cancer patients were diagnosed with pancreatic cancer by pathology. Other systemic tumors, tumors metastatic to the pancreas, and other underlying diseases were excluded.
[0080] Patients with benign diseases include those with pancreatitis, benign pancreatic tumors, gallstones, etc.
[0081] Table 1 Statistics of selected cases:
[0082]
[0083] In Table 1 , the data of the NGS cohort and the RT-qPCR confirmation cohort were obtained by the applicants through self-testing of serum collected from the hospital.
[0084] In Table 1, the data of RT-qPCR validation cohorts 1 and 2 (including the detection data of miRNA and CA19-9) came from two different hospitals, respectively. The data were obtained by Beijing Regen Biotechnology Co., Ltd. by entrusting the hospitals with testing reagents.
[0085] That is, the data of the RT-qPCR confirmation cohort, RT-qPCR validation cohort 1, and RT-qPCR validation cohort 2 were obtained from different centers.
[0086] In Table 1 , RT-qPCR validation cohorts 1&2 are the combined datasets of RT-qPCR validation cohorts 1 and 2.
[0087] 2. Isolation and purification of extracellular vesicles
[0088] Use a vacuum blood collection tube (coagulant / separation gel) for venous blood collection, and separate the serum by centrifugation at 2000×g for 10 minutes at 10℃~30℃ within 6 hours after blood collection. The serum samples after the above treatment must be used for testing immediately, or stored at -70℃ or below for no more than 12 months, and repeated freezing and thawing is strictly prohibited. Extracellular vesicles are isolated using GlyExo-Capture extracellular vesicle extraction reagent, in which the magnetic beads used are "a lectin-magnetic carrier coupling complex for isolating glycosylated extracellular vesicles in clinical samples" (application number: 202010060055.7).
[0089] 3. Extraction and NGS sequencing of extracellular vesicle miRNA
[0090] use The total RNA of extracellular vesicles was extracted using the Mini Kit and evaluated using the high-sensitivity RNA kit of the Qsep100 fully automated nucleic acid analysis system. Then, the extracellular vesicle small RNA was transcribed into a cDNA library using the Illumina NEBNext smallRNA library preparation kit, and the library of the target size fragment was selected and purified using the E-Gel Power Snap electrophoresis system and the E-Gel SizeSelect II gel. After checking the quality and concentration of the cDNA library, 75nt, single-end sequencing was performed on the Illumina NextSeq 550 sequencing system, and the sequencing data volume of a single library was greater than 10M reads.
[0091] 4. Construct miRNA interaction network and analyze NGS sequencing data to obtain characteristic miRNA pairs of pancreatic cancer through single factor screening and genetic algorithm screening.
[0092] (1) Construction of miRNA interaction network
[0093] 1) Obtain miRNA targets from the miRTarBase database;
[0094] 2) Based on the target information of miRNA obtained in step 1), the transcription factors that can serve as the targets of miRNA are screened from the human transcription factor database hTFtarget and AnimalTFDB;
[0095] 3) Based on the transcription factors screened in step 2), the miRNAs further regulated by them are obtained through bioinformatics methods or public databases, thereby constructing the interaction relationship between miRNA-TF-miRNA and obtaining the miRNA interaction network.
[0096] (2) Analyze NGS sequencing data and prepare miRNA quantification data
[0097] By analyzing the above NGS sequencing data, the miRNA quantitative data of each sample in the comprehensive sample set including disease samples and control samples were obtained:
[0098] First, the original sequencing file in fastq format is required for quality control. Based on the quality control results, cutadapt software is used to remove adapters and low-quality reads. For data that pass the quality control, the exceRpt small RNA analysis process is used for annotation and quantification to obtain the expression matrix. According to the expression level of the expression matrix, miRNAs with counts that are too low are filtered out (specific analysis is required for specific situations) to obtain corrected miRNA quantitative data.
[0099] (3) Construction of miRNA expression ratio features
[0100] Based on the miRNA interaction network constructed above and the prepared miRNA quantitative data, the expression ratios of the miRNA pairs with interacting relationships in each sample were calculated.
[0101] In order to avoid the phenomenon of denominator being 0, when calculating the miRNA expression ratio, the denominator is uniformly added with "1". The calculation formula is as follows:
[0102] miRNA_a / miRNA_b=counts a / (count b +1)
[0103] (4) Screening of characteristic miRNA pairs
[0104] Through single factor screening and genetic algorithm screening, characteristic miRNA pairs of pancreatic cancer were obtained. The basic process is as follows:
[0105] i) Single factor screening: Compare the expression ratios of each miRNA pair in the disease biological sample group relative to the normal biological sample group, use python's scipy.stats.ttest_ind to calculate the p value, and use statsmodels.stats.multitest.fdrcorrection to correct the p value. For the corrected p value p-adjusted, screening is performed based on a threshold of 0.05;
[0106] ii) For the screened miRNA pairs, the logarithm of the change fold of the expression ratio in the disease biological sample group relative to the expression ratio in the normal biological sample group, i.e., log2FoldChange, is calculated, and a suitable threshold for log2FoldChange is selected according to the actual situation to further screen suitable targets;
[0107] iii) The genetic algorithm was used for further screening after 100 cycles.
[0108] Serum samples from 78 pancreatic cancer patients and 38 benign disease patients were collected as NGS cohorts (as shown in Table 1). NGS was used to measure the expression of miRNAs in glycosylated extracellular vesicles and construct paired miRNAs. After the above screening procedure, 39 paired miRNA expression ratios were obtained. A heat map of the expression ratios of these 39 paired miRNAs on the NGS cohort was drawn, see Figure 1 .
[0109] Figure 1 It shows that there is an obvious clustering effect between cancer samples and benign samples in the heat map, that is, the expression ratios of 39 paired miRNAs perform well in the NGS cohort.
[0110] Example 2: Validation of 39 paired miRNAs in RT-qPCR data
[0111] Serum samples from 103 pancreatic cancer patients, 66 benign disease patients, and 56 healthy subjects were collected as the RT-qPCR confirmation cohort (as shown in Table 1). The CT values of the 39 paired miRNAs obtained in Example 1 were measured using the RT-qPCR method to confirm whether the differences still existed at the RT-qPCR level.
[0112] The method of RT-qPCR is:
[0113] 1) Use Mini Kit was used to extract total RNA from extracellular vesicles and synthesize first-strand cDNA by reverse transcription. The reaction system and reaction conditions are as follows:
[0114] Reaction system and volume:
[0115] Reaction system Volume (μL) Reverse transcription primer (20 μM) 1 5× Reverse Transcription Buffer 2 Poly A polymerase (5U / μL) 0.5 Reverse transcriptase (200 U / μL) 0.5 ATP(10mM) 0.5 dNTP(10mM) 0.5 RNA template 5 Total volume 10 .
[0116] Reaction conditions and time:
[0117]
[0118]
[0119] Then, miRNA RT-qPCR reaction was performed on the ABI 7500 real-time fluorescence quantitative PCR system. The reaction system and reaction conditions were as follows:
[0120] Reaction system and volume:
[0121] Reaction system Volume (μL) 2×RT-qPCR reaction solution 12.5 Forward primer (10 μM) 2 Reverse primer (10 μM) 2 Probe (10 μM) 1 Rox 0.5 Nuclease-free water 2 cDNA 5 Total volume 25 .
[0122] Reaction conditions and time:
[0123]
[0124] The primers can be designed according to conventional methods.
[0125] The LDA graph was drawn based on the CT value test results of RT-qPCR. The LDA graph results of 39 paired miRNAs in PCR data are shown in the figure. Figure 2 , it can be seen that these 39 paired miRNAs can clearly distinguish pancreatic cancer, benign diseases, and healthy samples.
[0126] Example 3: Further screening and verification of characteristic miRNA pairs for pancreatic cancer (preferred combination 1)
[0127] Based on the pancreatic cancer, benign disease, and healthy samples of the RT-qPCR confirmation cohort, the 39 paired miRNAs were recursively eliminated using a logistic regression model (using diagnostic efficacy as a screening indicator, by removing one or more markers to screen out the marker combination with the best diagnostic performance), and 2 paired miRNAs were obtained (preferred combination 1):
[0128] hsa-miR-98 / hsa-miR-25
[0129] hsa-miR-378i / hsa-miR-150
[0130] Using the RT-qPCR quantitative data (refer to Example 2 for the RT-qPCR method), a box plot was performed to display the preferred combination (two paired miRNAs).
[0131] Among them, in the RT-qPCR program of the preferred combination 1, the primer sequences used are as follows:
[0132]
[0133] Box plots such as Figure 3 As shown: pancreatic cancer has significant differences compared with benign diseases and healthy samples (p<0.05), especially early pancreatic cancer also has significant differences compared with benign diseases and healthy samples (p<0.05).
[0134] A pancreatic cancer diagnostic model was constructed based on the preferred combination (hsa-miR-98 / hsa-miR-25, hsa-miR-378i / hsa-miR-150), and its diagnostic performance was verified: the RT-qPCR confirmation cohort shown in Table 1 was divided into a training set (24 cases of mid-to-late stage pancreatic cancer, 38 cases of early stage pancreatic cancer, 39 cases of benign diseases, and 34 healthy cases) and a test set (16 cases of mid-to-late stage pancreatic cancer, 25 cases of early stage pancreatic cancer, 27 cases of benign diseases, and 22 healthy cases) according to a ratio of 6:4. The model was established using logistic regression on the training set, verified on the test set, and verified on other external validation sets (RT-qPCR validation cohorts 1, 2, 1&2).
[0135] A logistic regression model was established for the two paired miRNAs in the training set (combination 1), and the cutoff was determined according to the maximum Youden index principle of the training set. The overall performance of the model was evaluated by the AUC, sensitivity and specificity of the ROC curve.
[0136] The AUC, sensitivity and specificity results of the ROC curve are as follows Figure 4 shown.
[0137] Figure 4The results showed that the preferred combination (hsa-miR-98 / hsa-miR-25, hsa-miR-378i / hsa-miR-150) achieved AUCs of 0.867 (sensitivity 0.806, specificity 0.808) and 0.963 (sensitivity 0.878, specificity 0.864) in the training set, test set, validation set 1 (i.e. validation cohort 1), validation set 2 (i.e. validation cohort 2), and validation set 1&2 (i.e. validation cohort 1&2), respectively, in distinguishing pancreatic cancer from other samples (benign disease, healthy). The sensitivity and specificity of hsa-miR-98 / hsa-miR-25 and hsa-miR-378i / hsa-miR-150 were 0.918 (sensitivity: 0.849, specificity: 0.898), 0.927 (sensitivity: 0.848, specificity: 0.845), and 0.934 (sensitivity: 0.848, specificity: 0.873). This indicates that the preferred combination (hsa-miR-98 / hsa-miR-25, hsa-miR-378i / hsa-miR-150) not only has excellent diagnostic efficacy, but also has stable diagnostic efficacy in different data centers, without unstable results.
[0138] In order to better evaluate the diagnostic efficacy of the model for early pancreatic cancer, under the optimal cutoff condition, the diagnostic sensitivity and specificity data of mid-to-late stage pancreatic cancer and early stage pancreatic cancer in samples from different data sets were obtained. The results are shown in Table 2.
[0139] Table 2. Sensitivity and specificity of the preferred combination in different data sets
[0140]
[0141] The results in Table 2 show that in the evaluation model, the recognition sensitivity of mid-late and early pancreatic cancer in different data sets is high. The recognition sensitivity of mid-late pancreatic cancer is above 0.750 (i.e. 75.0%), and the recognition sensitivity of early pancreatic cancer is above 0.763 (i.e. 76.3%). It can specifically distinguish other samples (benign diseases, health), and the diagnosis accuracy of pancreatic cancer is relatively high.
[0142] The sample score distribution box plot of this embodiment is as follows Figure 5 As shown, the results show that there are significant differences between the middle and late stages and early stages of pancreatic cancer and other samples (benign diseases, healthy) and the distinction effect is good.
[0143] In summary, the preferred combination of the present application (hsa-miR-98 / hsa-miR-25, hsa-miR-378i / hsa-miR-150) can effectively distinguish pancreatic cancer from other samples (benign diseases, health), and has a high sensitivity for early recognition of pancreatic cancer, and presents stable diagnostic results in data sets from different sources, which can improve the accuracy of early pancreatic cancer and is of great significance for the diagnosis, efficacy or prognosis evaluation of pancreatic cancer.
[0144] Example 4: Further screening and verification of characteristic miRNA pairs for pancreatic cancer (preferred combination 2)
[0145] Based on the pancreatic cancer, benign, and healthy samples of the PCR-confirmed cohort, the SVM model was used to perform recursive feature elimination on 39 paired miRNAs (using diagnostic efficacy as the screening index, removing one or more markers to screen out the marker combination with the best diagnostic performance), and 4 paired miRNAs were obtained (preferred combination 2):
[0146] hsa-miR-501 / hsa-miR-150
[0147] hsa-miR-378i / hsa-miR-155
[0148] hsa-miR-193a / hsa-miR-155
[0149] hsa-miR-150 / hsa-miR-1180
[0150] Using RT-qPCR quantitative data (refer to Example 2 for the RT-qPCR method), a box plot was performed to display the preferred combination of two (4 paired miRNAs).
[0151] Among them, in the RT-qPCR program of the preferred combination 2, the primer sequences used are as follows:
[0152]
[0153] Box plots such as Figure 6 As shown: Pancreatic cancer has significant differences compared with benign diseases and healthy samples (p<0.05).
[0154] A pancreatic cancer diagnostic model was constructed based on the preferred combination 2 (hsa-miR-501 / hsa-miR-150, hsa-miR-378i / hsa-miR-155, hsa-miR-193a / hsa-miR-155, hsa-miR-150 / hsa-miR-1180), and its diagnostic performance was verified: the RT-qPCR confirmation cohort shown in Table 1 was divided into a training set (24 cases of mid-to-late stage pancreatic cancer, 38 cases of early stage pancreatic cancer, 39 cases of benign diseases, and 34 healthy cases) and a test set (16 cases of mid-to-late stage pancreatic cancer, 25 cases of early stage pancreatic cancer, 27 cases of benign diseases, and 22 healthy cases) according to a ratio of 6:4. The model was established using logistic regression on the training set, verified on the test set, and verified on other external validation sets (RT-qPCR validation cohorts 1, 2, 1&2).
[0155] A logistic regression model was established for the four paired miRNAs in the training set (combination 2), and the cutoff was determined according to the maximum Youden index principle of the training set. The overall performance of the model was evaluated by the AUC, sensitivity and specificity of the ROC curve.
[0156] The AUC, sensitivity and specificity results of the ROC curve are as follows Figure 7 shown.
[0157] Figure 7 The results showed that the preferred combination 2 (hsa-miR-501 / hsa-miR-150, hsa-miR-378i / hsa-miR-155, hsa-miR-193a / hsa-miR-155, hsa-miR-150 / hsa-miR-1180) achieved AUCs of 0.888 (sensitivity 0.806, specificity 0.849), 0.879 (sensitivity 0.780, specificity 0.849) in the training set, test set, validation set 1 (i.e. validation cohort 1), validation set 2 (i.e. validation cohort 2), and validation set 1&2 (i.e. validation cohort 1&2), respectively, when distinguishing pancreatic cancer from other samples (benign diseases, healthy samples). The sensitivity and specificity of the two combinations were as follows: 0.944 (sensitivity 0.834, specificity 0.900), 0.931 (sensitivity 0.873, specificity 0.851), which indicated that the preferred combination two (hsa-miR-501 / hsa-miR-150, hsa-miR-378i / hsa-miR-155, hsa-miR-193a / hsa-miR-155, hsa-miR-150 / hsa-miR-1180) not only had excellent diagnostic efficacy, but also had stable diagnostic efficacy in different data centers, without unstable results.
[0158] In order to better evaluate the diagnostic efficacy of the model for early pancreatic cancer, under the optimal cutoff condition, the sensitivity and specificity data of mid-to-late stage and early stage pancreatic cancer in samples from different data sets were obtained. The results are shown in Table 3.
[0159] Table 3. Sensitivity and specificity of preferred combination 2 in different data sets
[0160]
[0161] The results in Table 3 show that in the evaluation model, the recognition sensitivity of mid-late and early pancreatic cancer in different data sets is high. The recognition sensitivity of mid-late pancreatic cancer is above 0.875 (i.e. 87.5%), and the recognition sensitivity of early pancreatic cancer is as high as 0.72 (i.e. 72%). It can specifically distinguish other samples (benign diseases, health), and the accuracy rate of early diagnosis of pancreatic cancer is high.
[0162] The sample score distribution box plot of this embodiment is as follows Figure 8 As shown, the results show that the model scores are significantly different in the middle and late stages, early stages of pancreatic cancer and other samples (benign diseases, healthy) and have a good discrimination effect.
[0163] In summary, the preferred combination two of the present application (hsa-miR-501 / hsa-miR-150, hsa-miR-378i / hsa-miR-155, hsa-miR-193a / hsa-miR-155, hsa-miR-150 / hsa-miR-1180) is described, and the sensitivity of early recognition of pancreatic cancer is also high, and stable diagnostic results are presented in data sets from different sources, which can improve the accuracy of early pancreatic cancer, and is of great significance for the diagnosis, efficacy or prognosis evaluation of pancreatic cancer.
[0164] Example 5: Construction of a pancreatic cancer diagnostic model based on paired miRNA preferred combination 1 and pancreatic cancer indicator CA19-9, and verification of its diagnostic performance
[0165] In this embodiment, the preferred combination 1 (hsa-miR-98 / hsa-miR-25, hsa-miR-378i / hsa-miR-150) and the pancreatic cancer indicator CA19-9 are used for joint modeling (wherein, the expression level of CA19-9 is detected by using a carbohydrate antigen 19-9 assay kit (magnetic microparticle chemiluminescence immunoassay), which is from Beijing Rejing Biotechnology Co., Ltd. and can be purchased externally), and the sample information of the training set and validation set used is consistent with that of Example 3 (the detection of CA19-9 is also a test conducted by the applicant who provides a kit and entrusts the corresponding hospital to perform the test). The specific modeling method is as follows:
[0166] The RT-qPCR confirmation cohort shown in Table 1 was divided into a training set (24 cases of advanced pancreatic cancer, 38 cases of early pancreatic cancer, 40 cases of benign diseases, and 34 healthy cases) and a test set (16 cases of advanced pancreatic cancer, 25 cases of early pancreatic cancer, 26 cases of benign diseases, and 22 healthy cases) in a ratio of 6:4. The model was established using logistic regression on the training set, validated on the test set, and validated on other external validation sets (RT-qPCR validation cohorts 1, 2, 1&2).
[0167] A logistic regression model was established for the two paired miRNAs (combination 1) and the pancreatic cancer indicator CA19-9 in the training set, and the cutoff was determined according to the maximum Youden index principle of the training set. The overall performance of the model was evaluated by the AUC, sensitivity and specificity of the ROC curve.
[0168] The AUC, sensitivity and specificity results of the ROC curve are as follows Fig. 9shown.
[0169] Fig. 9 The results showed that the preferred combination (hsa-miR-98 / hsa-miR-25, hsa-miR-378i / hsa-miR-150) and the pancreatic cancer indicator CA19-9 combined in distinguishing pancreatic cancer from other samples (benign disease, healthy) in the training set, test set, validation set 1 (i.e. validation cohort 1), validation set 2 (i.e. validation cohort 2), validation set 1&2 (i.e. validation cohort 1&2) AUCs were 0.942 (sensitivity 0.839, specificity 0.959), 0.975 (sensitivity 0.902, specificity The sensitivity and specificity of hsa-miR-98 / hsa-miR-25 and hsa-miR-378i / hsa-miR-150 were 0.896, 0.958 (sensitivity 0.839, specificity 0.924), 0.965 (sensitivity 0.795, specificity 0.936) and 0.961 (sensitivity 0.811, specificity 0.930), indicating that the preferred combination (hsa-miR-98 / hsa-miR-25, hsa-miR-378i / hsa-miR-150) and pancreatic cancer indicator CA19-9 not only further improved the diagnostic efficacy, but also the diagnostic efficacy of the results in different data centers was stable, and there was no unstable result.
[0170] In order to better evaluate the diagnostic efficacy of the model for early pancreatic cancer, under the optimal cutoff condition, the diagnostic sensitivity and specificity data of mid-to-late stage pancreatic cancer and early stage pancreatic cancer in samples from different data sets were obtained. The results are shown in Table 4.
[0171] Table 4. Sensitivity and specificity of combined diagnosis of preferred combination 1 and pancreatic cancer indicator CA19-9 in different data sets
[0172]
[0173]
[0174] The results in Table 4 show that in the evaluation model of combined diagnosis of the preferred combination 1 and the pancreatic cancer indicator CA19-9, the recognition sensitivity of mid-late and early pancreatic cancer in different data sets is high, the recognition sensitivity of mid-late pancreatic cancer is above 0.811 (i.e. 81.1%), and the recognition sensitivity of early pancreatic cancer is above 0.75 (i.e. 75.0%). It can specifically distinguish other samples (benign diseases, health), and the diagnosis accuracy of pancreatic cancer is relatively high.
[0175] Example 6: Construction of a pancreatic cancer diagnostic model based on the paired miRNA preferred combination 2 and the pancreatic cancer indicator CA19-9, and verification of its diagnostic performance
[0176] In this example, the preferred combination 2 (hsa-miR-501 / hsa-miR-150, hsa-miR-378i / hsa-miR-155, hsa-miR-193a / hsa-miR-155, hsa-miR-150 / hsa-miR-1180) and the pancreatic cancer indicator CA19-9 were used for joint modeling (wherein, the expression level of CA19-9 was detected using a carbohydrate antigen 19-9 assay kit (magnetic particle chemiluminescence immunoassay), which is from Beijing Rejing Biotechnology Co., Ltd. and can be purchased externally). The specific modeling method is as follows:
[0177] The RT-qPCR confirmation cohort shown in Table 1 was divided into a training set (24 cases of advanced pancreatic cancer, 38 cases of early pancreatic cancer, 40 cases of benign diseases, and 34 healthy cases) and a test set (16 cases of advanced pancreatic cancer, 25 cases of early pancreatic cancer, 26 cases of benign diseases, and 22 healthy cases) in a ratio of 6:4. The model was established using logistic regression on the training set, validated on the test set, and validated on other external validation sets (RT-qPCR validation cohorts 1, 2, 1&2).
[0178] A logistic regression model was established for the two paired miRNAs (combination 2) and the pancreatic cancer indicator CA19-9 in the training set, and the cutoff was determined according to the maximum Youden index principle of the training set. The overall performance of the model was evaluated by the AUC, sensitivity and specificity of the ROC curve.
[0179] The AUC, sensitivity and specificity results of the ROC curve are as follows Fig.10 shown.
[0180] Fig.10The results showed that the preferred combination of hsa-miR-501 / hsa-miR-150, hsa-miR-378i / hsa-miR-155, hsa-miR-193a / hsa-miR-155, hsa-miR-150 / hsa-miR-1180) and the pancreatic cancer indicator CA19-9 in distinguishing pancreatic cancer from other samples (benign disease, healthy) had an AUC of 0.963 (sensitivity 0.952, specificity 0.878) in the training set, test set, validation set 1 (i.e. validation cohort 1), validation set 2 (i.e. validation cohort 2), and validation set 1&2 (i.e. validation cohort 1&2), respectively. The sensitivity and specificity of hsa-miR-501 / hsa-miR-150 and hsa-miR-378i / hsa-miR-155 were 0.93a / hsa-miR-155 and 0.93b / hsa-miR-150, 0.978 (sensitivity and specificity, 0.891) and 0.964 (sensitivity and specificity, 0.851), indicating that the preferred combination of hsa-miR-501 / hsa-miR-150, hsa-miR-378i / hsa-miR-155, hsa-miR-193a / hsa-miR-155 and hsa-miR-150 / hsa-miR-1180 and pancreatic cancer indicator CA19-9 not only further improved the diagnostic efficacy, but also stabilized the diagnostic efficacy in different data centers without unstable results.
[0181] In order to better evaluate the diagnostic efficacy of the model for early pancreatic cancer, under the optimal cutoff condition, the diagnostic sensitivity and specificity data of mid-to-late stage pancreatic cancer and early stage pancreatic cancer in samples from different data sets were obtained. The results are shown in Table 5.
[0182] Table 5. Sensitivity and specificity of combined diagnosis of preferred combination II and pancreatic cancer indicator CA19-9 in different data sets
[0183]
[0184] The results in Table 5 show that in the evaluation model of the combined diagnosis of the preferred combination 2 and the pancreatic cancer indicator CA19-9, the recognition sensitivity of mid-late and early pancreatic cancer in different data sets is high, the recognition sensitivity of mid-late pancreatic cancer is above 0.937 (i.e. 93.7%), and the recognition sensitivity of early pancreatic cancer is above 0.925 (i.e. 92.5%). It can specifically distinguish other samples (benign diseases, health), and the diagnosis accuracy of pancreatic cancer is relatively high.
[0185] Comparative Example 1:
[0186] Although the advent of big data has improved the convenience of marker screening, it is still a great challenge to screen out marker combinations that are applicable to different data centers (different hospitals). Most of the time, the marker combinations with good diagnostic performance obtained by screening are difficult to apply to other data centers (other hospitals or institutions). For example, the applicant screened and obtained the following combination of paired miRNAs:
[0187] hsa-miR-501 / hsa-miR-25
[0188] hsa-miR-20b / hsa-miR-150
[0189] hsa-miR-193a / hsa-miR-150
[0190] Using RT-qPCR quantitative data (refer to Example 2 for the RT-qPCR method), a box plot of the combination of three (3 paired miRNAs) was performed.
[0191] Among them, in the RT-qPCR program of the preferred combination three, the primer sequences used are as follows:
[0192]
[0193]
[0194] Box plots such as Fig.11 As shown: Pancreatic cancer has significant differences compared with benign diseases and healthy samples (p<0.05).
[0195] A pancreatic cancer diagnostic model was constructed based on the combination of three (hsa-miR-501 / hsa-miR-25, hsa-miR-20b / hsa-miR-150, hsa-miR-193a / hsa-miR-150), and its diagnostic performance was verified: the RT-qPCR confirmation cohort shown in Table 1 was divided into a training set (24 cases of mid-to-late stage pancreatic cancer, 38 cases of early stage pancreatic cancer, 39 cases of benign diseases, and 34 healthy cases) and a test set (16 cases of mid-to-late stage pancreatic cancer, 25 cases of early stage pancreatic cancer, 27 cases of benign diseases, and 22 healthy cases) according to a ratio of 6:4. The model was established using logistic regression on the training set, verified on the test set, and verified on other external validation sets (RT-qPCR validation cohorts 1, 2, 1&2).
[0196] A logistic regression model was established for the three paired miRNAs in the training set (combination 3), and the cutoff was determined according to the maximum Youden index principle of the training set. The overall performance of the model was evaluated by the AUC, sensitivity and specificity of the ROC curve.
[0197] The AUC, sensitivity and specificity results of the ROC curve are as follows Fig.12 shown.
[0198] Fig.12 The results showed that the combination of hsa-miR-501 / hsa-miR-25, hsa-miR-20b / hsa-miR-150, and hsa-miR-193a / hsa-miR-150 could achieve AUCs of 0.886 (sensitivity 0.871, specificity 0.795) and 0.881 (sensitivity 0.829, specificity 0.776) in the training set and test set, respectively, when distinguishing pancreatic cancer from other samples (benign disease, healthy). That is, it showed good diagnostic performance in one data center (RT-qPCR confirmation cohort), but in other data centers, the AUCs in validation set 1 (i.e. validation cohort 1), validation set 2 (i.e. validation cohort 2), and validation set 1&2 (i.e. validation cohort 1&2) were only 0.607, respectively. (sensitivity 0.591, specificity 0.669), 0.696 (sensitivity 0.589, specificity 0.800), and 0.717 (sensitivity 0.669, specificity 0.751), indicating that although combination three (hsa-miR-501 / hsa-miR-25, hsa-miR-20b / hsa-miR-150, hsa-miR-193a / hsa-miR-150) showed good diagnostic performance in the randomly divided training set and test set in one data center (RT-qPCR confirmation cohort), the diagnostic performance in other data centers (validation sets 1 and 2 (i.e., RT-qPCR validation cohorts 1 and 2 in Table 1) came from other hospitals tested by a third party) was significantly reduced, that is, the diagnostic results were unstable and difficult to apply in clinical practice.
[0199] The diagnostic performance of the model for early pancreatic cancer was also evaluated. Under the optimal cutoff condition, the sensitivity and specificity data for mid-to-late stage and early stage pancreatic cancer in samples from different data sets were obtained. The results are shown in Table 6.
[0200] Table 6. Sensitivity and specificity of combination 3 in different data sets
[0201]
[0202] The results in Table 4 show that in the evaluation model, the sensitivity and specificity of the training set and test set randomly divided in the same data center for the middle and late stages and early stages of pancreatic cancer are high, especially the recognition sensitivity of the middle and late stages of pancreatic cancer in the training set is as high as 0.958 (95.8%), but in other data centers (validation sets 1 and 2 are from other hospitals tested by a third party), the sensitivity is significantly reduced (the recognition sensitivity is as low as below 0.5), and the diagnostic accuracy rate is also significantly reduced, that is, the diagnostic results are unstable and difficult to apply in clinical practice.
[0203] Comparative Example 2:
[0204] Internal reference genes are genes with relatively constant expression in various tissues and cells. They are generally used as references for detecting the expression level of target genes and play a certain correction role. Commonly used internal reference genes include 18S rRNA, 28S rRNA, U6, etc. Although their expression is relatively constant, their expression may be unstable under different conditions such as physiological or pathological changes, which may have a great impact on the analysis of target gene expression, resulting in great difficulties in the selection and application of diagnostic markers. For example, the hsa-miR-98 / hsa-miR-25 miRNA pair in Example 3 can significantly distinguish pancreatic cancer from other samples (see Figure 3 However, when hsa-miR-98 and hsa-miR-25 were calibrated with the conventional internal reference gene U6, and hsa-miR-98 and hsa-miR-25 were used as markers, it was found that: hsa-miR-98 could distinguish pancreatic cancer from healthy samples (p<0.05), but could not distinguish pancreatic cancer from benign pancreatic diseases; hsa-miR-25 could distinguish pancreatic cancer from benign pancreatic diseases (p<0.05), but could not distinguish pancreatic cancer from healthy samples (see Fig.13 Box plot display), specifically:
[0205] Using RT-qPCR quantitative data (RT-qPCR method refers to Example 2), box plots of hsa-miR-98, hsa-miR-25, and hsa-miR-98 / hsa-miR-25 were displayed, where hsa-miR-98 and hsa-miR-25 represent the box plots of hsa-miR-98 and hsa-miR-25 expression levels corrected by the internal reference gene U6. Fig.13 The box plot of hsa-miR-98 / hsa-miR-25 is shown in Figure 3 Left picture.
[0206] Among them, the primer sequences used for hsa-miR-98, hsa-miR-25, and U6 are as follows:
[0207]
[0208] Fig.13The results showed that when the expression levels of hsa-miR-98 and hsa-miR-25 were corrected with U6 as the internal reference gene, the expression levels of pancreatic cancer samples were sometimes not significantly correlated with the expression levels of other samples (for example, hsa-miR-98 could not significantly distinguish between pancreatic cancer and benign patients, and hsa-miR-25 could not distinguish between pancreatic cancer and healthy people), indicating that the diagnostic performance was unstable when the expression levels of hsa-miR-98 and hsa-miR-25 were corrected with common internal reference genes (such as U6).
[0209] In summary, the preferred combination one (hsa-miR-98 / hsa-miR-25, hsa-miR-378i / hsa-miR-150) and preferred combination two (hsa-miR-501 / hsa-miR-150, hsa-miR-378i / hsa-miR-155, hsa-miR-193a / hsa-miR-155, hsa-miR-150 / hsa-miR-1180) screened by the present invention are marker combinations that are suitable for different data centers and have good diagnostic performance and diagnostic stability, which are obtained by continuously adjusting the screening method or screening conditions. When they are combined with the pancreatic cancer indicator CA19-9 for diagnosis, the diagnostic performance can be further improved, and they have good clinical application prospects.
[0210] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims
1. A diagnostic or prognostic marker combination for pancreatic cancer, characterized in that: The diagnostic or prognostic marker for pancreatic cancer comprises a marker combination consisting of at least two or at least four of the following miRNAs: hsa-miR-98, hsa-miR-25, hsa-miR-378i, hsa-miR-150, hsa-miR-501, hsa-miR-155, hsa-miR-193a, hsa-miR-1180.
2. The diagnostic or prognostic marker combination for pancreatic cancer according to claim 1, characterized in that: The diagnostic or prognostic markers for pancreatic cancer include one or more of the following miRNA combinations: hsa-miR-98 and hsa-miR-25, optionally, hsa-miR-25 is used to calibrate the relative expression of hsa-miR-98; hsa-miR-378i and hsa-miR-150, optionally, hsa-miR-150 is used to calibrate the relative expression of hsa-miR-378i; hsa-miR-501 and hsa-miR-150, optionally, hsa-miR-150 is used to calibrate the relative expression of hsa-miR-501; hsa-miR-378i and hsa-miR-155, optionally, hsa-miR-155 is used to calibrate the relative expression of hsa-miR-378i; hsa-miR-193a and hsa-miR-155, optionally, hsa-miR-155 is used to calibrate the relative expression of hsa-miR-193a; hsa-miR-150 and hsa-miR-1180, optionally, hsa-miR-1180 is used to calibrate the relative expression level of hsa-miR-150.
3. The diagnostic or prognostic marker combination for pancreatic cancer according to claim 2, characterized in that: The diagnostic or prognostic marker for pancreatic cancer comprises one or two of the following miRNA combinations 1) to 2): 1) Combination 1: hsa-miR-98, hsa-miR-25, hsa-miR-378i, hsa-miR-150; 2) Combination two: hsa-miR-501, hsa-miR-150, hsa-miR-378i, hsa-miR-155, hsa-miR-193a, hsa-miR-1180.
4. The diagnostic or prognostic marker combination for pancreatic cancer according to any one of claims 1 to 3, characterized in that: The miRNA in the miRNA pair is a miRNA in serum or plasma; And / or, the miRNA in the miRNA pair is a miRNA in serum or plasma glycosylated extracellular vesicles.
5. The diagnostic or prognostic marker combination for pancreatic cancer according to any one of claims 1 to 4, characterized in that: The diagnostic or prognostic markers for pancreatic cancer also include CA19-9.
6. An analysis system for predicting pancreatic cancer or evaluating the prognosis of pancreatic cancer, characterized in that: The invention comprises a data analysis module, wherein the data analysis module is used to analyze the expression of the marker combination of the target object to be predicted and calculate the expression ratio of the miRNA pair or directly use the expression ratio of the miRNA pair as an input feature, and is also used to calculate the prediction value of whether the target object is pancreatic cancer according to the expression ratio of the miRNA pair; the input feature is selected from at least one of the following expression ratios of the miRNA pair: hsa-miR-98 / hsa-miR-25; hsa-miR-378i / hsa-miR-150; hsa-miR-501 / hsa-miR-150; hsa-miR-378i / hsa-miR-155; hsa-miR-193a / hsa-miR-155; hsa-miR-150 / hsa-miR-1180.
7. The analysis system according to claim 6, characterized in that The input features are selected from one of the following combinations: 1) Combination 1: hsa-miR-98 / hsa-miR-25, hsa-miR-378i / hsa-miR-150; 2) Combination two: hsa-miR-501 / hsa-miR-150; hsa-miR-378i / hsa-miR-155; hsa-miR-193a / hsa-miR-155; hsa-miR-150 / hsa-miR-1180.
8. The analysis system according to claim 6 or 7, characterized in that: The data analysis module stores a prediction model for outputting a probability value of pancreatic cancer, wherein the method for constructing the prediction model includes: using the ratio of the expression levels of the miRNA pairs in pancreatic cancer, benign, and healthy samples as input variables, and whether it is pancreatic cancer as a dependent variable, calculating through multivariate logistic regression, obtaining a prediction model, and testing it through a validation set; and / or, when the detection method is RT-qPCR, the expression ratio is the CT difference of the miRNA pair; And / or, the input features also include the expression level of CA19-9 of the target object to be predicted.
9. Use of the pancreatic cancer diagnostic or prognostic marker combination according to any one of claims 1 to 5 in the preparation of a kit or analysis system for pancreatic cancer diagnosis, efficacy or prognosis evaluation, or related drug evaluation.
10. Use of the relative expression level of the diagnostic or prognostic marker combination for pancreatic cancer described in any one of 1 to 5 in serum or plasma glycosylated extracellular vesicles in the preparation of a kit or analysis system for pancreatic cancer diagnosis, efficacy or prognosis evaluation, or related drug evaluation, optionally, the marker combination is selected from one of the following combinations: 1) Combination 1: the expression level of hsa-miR-98 relative to hsa-miR-25, and the expression level of hsa-miR-378i relative to hsa-miR-150; 2) Combination 2: the expression level of hsa-miR-501 relative to hsa-miR-150; the expression level of hsa-miR-378i relative to hsa-miR-155; the expression level of hsa-miR-193a relative to hsa-miR-155; the expression level of hsa-miR-150 relative to hsa-miR-1180.
11. A kit for pancreatic cancer diagnosis, efficacy or prognosis evaluation, or related drug evaluation, characterized in that: The kit comprises the diagnostic or prognostic marker combination for pancreatic cancer according to any one of claims 1 to 5 and / or a detection reagent thereof.
12. The kit according to claim 11, characterized in that In pancreatic cancer patients, the expression ratio of the miRNA pair in serum glycosylated extracellular vesicles is significantly different from that in healthy humans.
13. The kit according to claim 11 or 12, characterized in that The detection reagents include primers and probes of the corresponding miRNAs, wherein the sequences of the primers and probes of the miRNAs are as follows: The nucleotide sequence of the upstream primer of hsa-miR-150 is shown in SEQ ID NO: 1; The nucleotide sequence of the upstream primer of hsa-miR-25 is shown in SEQ ID NO: 2; The nucleotide sequence of the upstream primer of hsa-miR-378i is shown in SEQ ID NO: 3; The nucleotide sequence of the upstream primer of hsa-miR-98 is shown in SEQ ID NO:4; The nucleotide sequence of the upstream primer of hsa-miR-1180 is shown in SEQ ID NO:6; The nucleotide sequence of the upstream primer of hsa-miR-501 is shown in SEQ ID NO:7; The nucleotide sequence of the upstream primer of hsa-miR-193a is shown in SEQ ID NO:8; The nucleotide sequence of the upstream primer of hsa-miR-155 is shown in SEQ ID NO:9; The nucleotide sequence of the probe is shown in SEQ ID NO:5; The reverse primer is a common downstream primer, and its nucleotide sequence is shown in SEQ ID NO:
10.
14. The kit according to claim 13, characterized in that Primers and probes that do not contain conventional internal reference genes.
Citation Information
Patent Citations
Lectin-magnetic carrier coupled complex used for separating glycosylated exosomes in clinical samples
CN111253491A
MiRNA group for early diagnosis and / or prognosis monitor of pancreatic caner and application of miRNA
CN111172285A
Detection reagent of biomarker for early diagnosis of pancreatic cancer
CN111748629A
Pancreatic cancer related serum microRNA marker and pancreatic cancer diagnosis method
CN118516459A
Microrna assay for detection and management of pancreatic cancer precursors
US20170022571A1
